Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04238728 · ClinicalTrials.gov registry record · Phase 1
Silverlon to Reduce Radiation Dermatitis
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04238728 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 31 participants.
The verdict
NCT04238728, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a silver-nylon dressing (Silverlon®, Argentum Medical) is useful for the prevention or treatment of radiation dermatitis in patients receiving radiation therapy to the breast.
Interventions
- DEVICE Silverlon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2022-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04238728
The ClinicalTrials.gov registry entry for NCT04238728 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Silverlon is the first listed.
NCT04238728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04238728 about?
NCT04238728 is a clinical study titled "Silverlon to Reduce Radiation Dermatitis". The purpose of this study is to see if a silver-nylon dressing (Silverlon®, Argentum Medical) is useful for the prevention or treatment of radiation dermatitis in patients receiving radiation therapy to the breast.
What is the current status of trial NCT04238728?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2020-08-31. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT04238728?
The interventions under investigation include: Silverlon (DEVICE).
Who is sponsoring clinical trial NCT04238728?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.